Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
CHMP recommends conditional approval for first GPP treatment
CHMP recommends conditional marketing authorization for novel IL-36 receptor monoclonal antibody, spesolimab, as first treatment for generalized pustular psoriasis flares
Treatment of hypertension. For the reduction of the risk of myocardial infarction (heart attack), stroke or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take A
Partnership with Precision Health Research, Singapore
Boehringer Ingelheim joins forces with Precision Health Research, Singapore with the aim of transforming healthcare and improving patient outcomes in Singapore and beyond.